HILLEMAN JERYL L 4

What Happened

• Jeryl L. Hilleman, a director of NovoCure Ltd (NVCR), sold 2,945 shares on June 2, 2026. The weighted-average sale price was $15.77, producing gross proceeds of about $46,445. The sales were executed in multiple trades at prices ranging from $15.65 to $15.88.
• This transaction was a sell-to-cover to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units (RSUs), as required by the company's award agreement, and therefore was not a discretionary open-market liquidation.

Key Details

• Transaction date: 2026-06-02; Form 4 filed: 2026-06-03 (timely).
• Action: Sale (S); shares sold: 2,945; weighted-average price: $15.77; price range: $15.65–$15.88; proceeds ≈ $46,445.
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes: F1 — sale mandated to cover tax withholding on RSU vesting (not discretionary). F2 — multiple trades; reported price is weighted average.
• Filing appears timely (no late-filing indication).

Context

• Sell-to-cover transactions are routine administrative sales to pay taxes when equity awards vest and generally do not indicate a director’s view on the company’s prospects. Purchases typically convey more direct positive signals than mandated withholding sales.